首页> 外文OA文献 >Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV‐infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine

【2h】

Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV‐infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine

机译：用替诺福韦富马酸盐治疗富马酸盐使艾滋病毒感染患者的脂质曲线与替诺福韦解毒富马酸盐进行治疗，每种与Elvitegravir，Cobicistat和Emtrickabine的Coformulated

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Purificación Cid‐Silva; Noelia Fernández‐Bargiela; Luis Margusino‐Framiñán; Vanesa Balboa‐Barreiro; Álvaro Mena‐De‐Cea; Soledad López‐Calvo; Pilar Vázquez‐Rodríguez; Isabel Martín‐Herranz; Enrique Míguez‐Rey; Eva Poveda; Ángeles Castro‐Iglesias;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV‐infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine [J] . Cid‐Silva Purificación, Fernández‐Bargiela Noelia, Margusino‐Frami?án Luis, Basic & clinical pharmacology & toxicology. . 2019,第4期

机译：用替诺福韦富烯酰胺富马酸盐治疗艾滋病毒感染患者的脂质曲线与替诺福韦解毒富马酸薄荷酸，每次与ElviteGravir，Cobicistat和Emtrickabine的Coformulated
2. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine [J] . Cid-Silva Purificacion, Fernandez-Bargiela Noelia, Margusino-Framinan Luis, Basic & clinical pharmacology & toxicology. . 2019,第S1期

机译：用替诺福韦富烯酰胺富马酸盐治疗艾滋病毒感染患者的脂质曲线与替诺福韦解毒富马酸薄荷酸，每次与ElviteGravir，Cobicistat和Emtrickabine的Coformulated
3. Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate [J] . Margot Nicolas, Cox Stephanie, Das Moupali, Antiviral therapy . 2017,第5期

机译：在用ElviteGravir / Cobicistat / Emtricistabine / Tenofovir Alafenaine或ElviteGravir / Cobicistat / Emtrickavir / Emtrickavir / Emtricicabine / Tenofovir Disocroxil umarate后，难以在96周的治疗后抗毒性抗药性治疗 - 幼稚科目
4. Modeling and simulation for dynamics of tenofovir disoproxil fumarate anti-HBV infection therapy [C] . Xiao Chen, Jianlong Qiu, Weiqi Qin, Chinese Automation Congress . 2017

机译：替诺福韦富马酸替诺福韦抗乙肝病毒感染治疗动力学建模与仿真
5. Cost effectiveness analysis of abacavir/lamivudine versus tenofovir/emtricitabine combination therapy as part of highly active antiretroviral therapy in treatment naive HIV-infected patients. [D] . Giguere, Pierre. 2010

机译：阿巴卡韦/拉米夫定与替诺福韦/恩曲他滨联合疗法作为高活性抗逆转录病毒疗法治疗未受HIV感染的患者的成本效益分析。
6. Week 48 Results of EMERALD: A Phase 3 Randomized Non-inferiority Study Evaluating the Efficacy and Safety of Switching from Boosted-protease Inhibitors (bPI) Plus Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF) Regimens to the Once Daily (QD) Single-tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Virologically Suppressed HIV-1-infected Adults [O] . Chloe Orkin, Jean-Michel Molina, Joel Gallant, 2017

机译：EMERALD的第48周结果：第3阶段的非劣效性研究评估了从加强蛋白酶抑制剂（bPI）加恩曲他滨（FTC）/替诺福韦富马酸替诺福韦酯（TDF）转换为每日一次（QD）的功效和安全性）在病毒学上被抑制感染了HIV-1的成年人中Darunavir / Cobicistat / Emtricitabine / Tenofovir Alafenamide（D / C / F / TAF）的单片治疗方案（STR）
7. A randomized, double-blind comparison of tenofovir alafenamide versus tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine for initial HIV-1 treatment: Week 96 results [O] . Wohl David D., Cheret Antoine A., Brunetta Jason J., 2016

机译：替诺福韦阿拉芬酰胺和替诺福韦富马酸替诺福韦的随机，双盲比较，每种药物与elvitegravir，cobicistat和恩曲他滨共同配制：最初的HIV-1治疗：第96周结果

Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV‐infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine

著录项

引文网络

相似文献

相关主题

期刊订阅